ARCT - NASDAQ
Arcturus Therapeutics Holdings Inc.
$7.60
+0.80%Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
At a Glance
Live SnapshotArcturus Therapeutics Holdings Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Arcturus Therapeutics Holdings Inc. Cash Flow Statement
ARCT • NASDAQ
| Arcturus Therapeutics Holdings Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||||
-65.8M | -80.9M | -29.7M | 9.3M | -203.7M | -72.1M | -26M | -21.8M | -10.9M | -24.6M | -19.4M | -32.8M | -10.5M | -1.6M | -3.9M | |
3M | 3.5M | 3M | 1.5M | 1.2M | 882K | 684K | 582K | 410K | 61K | 51K | 31K | 8K | 7K | 6K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 25K | 302K | 0.0 | 0.0 | -2.4M | -4.1M | 1K | 0.0 | 0.0 | |
25.4M | 38M | 34.6M | 30.6M | 28.9M | 6.8M | 2M | 1.3M | 2.2M | 2.5M | 2.4M | 4.1M | 1.5M | 26K | 1.6M | |
2.3M | 471K | -33.4M | 3.1M | 5.9M | 425K | 873K | 38K | 498K | 123K | 2.4M | 4.1M | 203K | 62K | 0.0 | |
(0.0) | (1.4M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (35K) | (12K) | (1K) | (0.0) | (0.0) | (0.0) | (0.0) | |
-39.2M | -20.8M | 7.4M | -12.6M | 32.6M | 21.2M | 16M | -1.2M | 7.4M | 2.7M | -1.1M | 388K | 1.4M | -101K | 9K | |
-74.3M | -59.7M | -18.1M | 32M | -135M | -42.9M | -6.4M | -20.8M | -460K | -19.2M | -18.1M | -28.3M | -7.4M | -1.6M | -2.4M | |
INVESTING ACTIVITIES | |||||||||||||||
-230K | -648K | -2.9M | -7.7M | -3.4M | -1.7M | -818K | -1.5M | -251K | -74K | -181K | -79K | -39K | (0.0) | -24K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (29K) | -20M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -6.6M | (0.0) | -17.4M | -33.5M | (0.0) | -28M | (0.0) | -517K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 30.2M | 10.6M | 22.3M | 0.0 | 8.5M | 0.0 | 519K | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 23.6M | 29K | 20M | -161K | 8.5M | -28M | 507K | -500K | |
-230K | -648K | -2.9M | -7.7M | -3.4M | -1.7M | -818K | (22.1M) | (10.4M) | (4.9M) | -33.8M | (8.4M) | -28M | (1M) | -1M | |
FINANCING ACTIVITIES | |||||||||||||||
13.4M | 682K | 609K | 411K | 515K | 423.8M | 21.3M | 0.0 | 477K | 0.0 | 66.5M | 0.0 | 57.3M | 1K | 2.2M | |
0.0 | 0.0 | -27.4M | -5M | 46.6M | 0.0 | 4.9M | 9.9M | 5.7M | 0.0 | 1.9M | 0.0 | 115K | 600K | 450K | |
0.0 | 4.7M | 2.7M | 1.7M | 902K | 12.3M | 15.7M | 332K | 1.3M | 6K | -66.5M | 0.0 | 29K | 0.0 | 0.0 | |
13.4M | 5.4M | -24.1M | -2.9M | 48M | 436.1M | 41.9M | 10.2M | 7M | 6K | 66.5M | 0.0 | 57.4M | 601K | 2.6M | |
CASH FLOW SUMMARY | |||||||||||||||
-61.1M | -55M | -45.1M | 21.4M | -90.4M | 391.5M | 34.6M | 11.6M | 16.9M | -14.4M | 14.5M | -19.9M | 22M | 42K | -782K | |
293.9M | 348.9M | 394M | 372.6M | 463M | 71.5M | 36.8M | 25.2M | 8.3M | 16.7M | 2.2M | 22.1M | 97K | 55K | 837K | |
232.8M | 293.9M | 348.9M | 394M | 372.6M | 463M | 71.5M | 36.8M | 25.2M | 2.3M | 16.7M | 2.2M | 22.1M | 97K | 55K | |
-74.3M | -60.4M | -21M | 24.3M | -138.4M | -44.6M | -7.3M | -22.2M | -711K | -19.3M | -18.3M | -28.4M | -7.4M | -1.6M | -2.4M |
SEC Filings
ARCT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 01, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 03, 2026 | December 31, 2025 | 2025 | |
S-3 S-3 N/A | December 30, 2025 | December 30, 2025 | ||
8-K 8-K 2025 N/A | December 15, 2025 | December 11, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 22, 2025 | October 22, 2025 | 2025 |
Related Guides
Continue your ARCT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.